

1 **Efficacy and safety of convalescent plasma versus standard care in hospitalized**
2 **patients with COVID-19 from the Peruvian Social Security Health System: open-**
3 **label, randomized, controlled clinical trial**

4

5 **Cristian Villanueva¹, Ibeth Neyra¹, Arturo Sagastegui¹, Ausberto Chunga¹, Martin**
6 **Oyanguren¹, Martina Guillermo-Roman², Suly Soto-Ordoñez², Jorge L. Maguiña²,**
7 **Yamilee Hurtado-Roca², Percy Soto-Becerra², Roger V. Araujo-Castillo²**

8 ¹Hospital Nacional Edgardo Rebagliati Martins, EsSalud, Lima, Perú.

9 ²Instituto de Evaluación de Tecnologías en Salud e Investigación – IETSI, EsSalud, Lima,
10 Perú

11

12 *** Corresponding:**

13 Roger V. Araujo-Castillo, MD

14 Address: Cápac Yupanqui 1400 - Jesus María, Lima 11, Perú

15 Phone: (511) 748 1111 ext 2143

16 E-mail: araujocaroger@gmail.com

17

18 **Financing**

19 This clinical trial has been co-financed by two institutions of the Government of Peru, the
20 Institute for the Evaluation of Technologies in Health and Research - IETSI of the Social
21 Security of Health (EsSalud) and the National Council of Science, Technology and
22 Technological Innovation (CONCYTEC) through peer-reviewed external financing: the
23 National Fund for Scientific Research, Technological Development and Technological
24 Innovation (FONDECYT), subsidy (N° 068-2020-FONDECYT). This grant was awarded

25 to CV, IN, AS, AC, MO, JLM, YH, PSB and RA. The funders had no role in study design,
26 data collection and analysis, decision to publish, or manuscript preparation.

27

28 **Conflicts of interest**

29 The authors declare not to have any interest conflicts.

30

31 **Data availability**

32 The raw data was generated at the Institute for the Evaluation of Technologies in Health
33 and Research - IETSI of Peru's Social Security of Health (EsSalud). Restrictions apply to
34 the public availability of these data due to institutional patient data sharing policies.
35 However, the data is available upon reasonable request from the author.

36

37 **Clinical Trial Registration Number:** This clinical trial has been registered in the
38 Peruvian Registry of Clinical Trials (REPEC, by Spanish acronym) with the following
39 ID: PER-013-20.

40

41 **ABSTRACT**

42 **OBJECTIVES:** To assess the efficacy and safety of convalescent plasma plus standard
43 of care (CP + SoC) compared with standard of care (SoC) alone in patients hospitalized
44 for moderate to severe COVID-19 who do not yet require mechanical ventilation.

45 **METHODS:** Phase 2 randomized, parallel-group, randomized, open-label, controlled,
46 superiority, single-center clinical trial. This clinical trial has been registered in REPEC
47 with the following ID: 013-20. Hospitalized adult patients with moderate to severe
48 COVID-19 were enrolled. The allocation ratio was 1:1 in a variable-size permuted block
49 randomization scheme. The primary outcome was death 28 days after the intervention.
50 Secondary outcomes were mortality at 14 and 56 days, time to death at 56 days, time in
51 the ICU at 28 days, time on a mechanical ventilator at 28 days, frequency of adverse
52 events, and frequency of serious adverse events.

53 **RESULTS:** A total of 64 participants were enrolled, 32 were assigned to CP + SoC, and
54 32 to SoC. One participant assigned to CP + SoC withdrew his informed consent before
55 applying the treatment. At day 28, there were no statistically significant differences for
56 the primary outcome between the CP + SoC and SoC groups (relative risk: 2.06; 95%CI
57 0.73 to 7.11; $p = 0.190$). No differences were found in the incidences of mortality at 56
58 days (hazard ratio: 2.21; 95%CI 0.66 to 7.33; $p = 0.182$), admission to the ICU at 28 days
59 (sub-hazard ratio: 2.06; 95%CI 0.57 to 8.55; $p = 0.250$), admission to mechanical
60 ventilation at 28 days (sub-hazard ratio: 2.19; 95%CI 0.57 to 8.51; $p = 0.260$). Estimates
61 for days 14 were similar. No infusion-related adverse events were reported during the
62 study. There were no statistically significant differences in the frequency of any adverse
63 events (odds ratio: 2.74; 95%CI 0.90 to 9.10; $p = 0.085$) or the frequency of serious
64 adverse events (odds ratio: 3.60; 95%CI 0.75 to 26.1; $p = 0.75$).

65 **CONCLUSIONS:** No evidence was found that CP had a significant effect in reducing
66 28-day mortality. There was also no evidence that the frequency of adverse events was
67 higher in those who received CP + SoC than those who received only SoC.

68

69 **Key Words:** Convalescent plasma, COVID-19, SARS-CoV-2, clinical trial.

70

71

72 **Introduction**

73 The SARS-CoV-2 virus causes coronavirus disease 2019 (COVID-19), identified in
74 Wuhan, China, in December 2019 and declared a pandemic on March 12, 2020, a few
75 months after the first case was reported (1–3). In the absence of available treatments,
76 clinical trials initially focused on evaluating the replacement of interventions with
77 recognized efficacy for other infectious diseases, such as antiparasitic, antiviral, anti-
78 inflammatory drugs, anticoagulants, and convalescent plasma, among others (4).

79

80 For more than a century, convalescent plasma (CP) has been used in the treatment of
81 various diseases of viral origin: severe acute respiratory syndrome (SARS), Eastern
82 respiratory syndrome (MERS), avian influenza A (H5N1), Spanish flu A H1N1
83 pandemic, among others (5,6). Theoretically, antibodies in the plasma of recovered
84 COVID-19 individuals would be passive immunization agents for the immune system of
85 patients with active disease (7); however, empirical evidence about its efficacy on
86 important outcomes was anecdotal, coming mainly from case series or observational
87 studies (5).

88

89 Initially, the studies showed conflicting evidence, and even the available systematic
90 reviews and meta-analyses did not find consistent results (8–12). Some systematic
91 reviews and meta-analyses concluded that PC shows a potential reduction in mortality,
92 although with statistically uncertain estimates (8–10). However, other systematic reviews
93 and meta-analyses concluded that PC does not offer any benefit to adverse outcomes of
94 COVID-19 (11,12), but the quality of the evidence reviewed was low. These inconsistent
95 results showed the need for more controlled clinical trials to clarify the uncertainty about
96 the efficacy of PC in the treatment of COVID-19.

97

98 This clinical trial was conducted in this context of uncertainty about the efficacy of PC.
99 However, as scientific evidence accumulated, it became increasingly clear that PC was
100 ineffective in treating patients hospitalized for COVID-19 (13). For this reason, this study
101 was terminated early. Although the current consensus indicates that there is high certainty
102 that treatment with PC is not effective in reducing outcomes of death, admission to the
103 ICU, or mechanical ventilation (13–15), there are still some controversies about whether
104 these studies evaluated the doses, appropriate application times (16–21) and uncertainties
105 about their safety (13). As of May 20, 2021, 100 clinical trials on CP had been registered,
106 but only under 33% had been published (13), so the publication of the findings will
107 contribute to resolving the uncertainties associated with CP therapy.

108

109 This study reports the results of a clinical trial that aimed to evaluate the efficacy and
110 safety of PC plus standard of care (SoC) compared to SoC alone in outcomes of patients
111 hospitalized for COVID-19. The main hypothesis of this clinical trial was that
112 convalescent plasma treatment in patients with moderate to severe COVID-19, who do
113 not yet require a mechanical ventilator, is effective in reducing 28-day mortality. Efficacy
114 against intensive care unit (ICU) admission, ventilator, and adverse events were also
115 evaluated. The article was written following the CONSORT 2010 guidelines
116 (Consolidated Standards of Reporting Trials) (22).

117

118 **Methods**

119 ***Study design***

120 Phase 2, randomized, controlled, open-label, parallel-group, superiority, single-center
121 clinical trial. The study was approved by the Transitory National Research Ethics

122 Committee (CNTEI) -COVID-19 through Certificate of Approval - CNTEI-007-2020
123 dated June 19, 2020. The study is registered in the Peruvian Registry of Clinical Trials
124 (REPEC) with code PER-013-20 (23) and was approved by the National Institute of
125 Health through Directorial Resolution 198-2020-OGITT-INS dated June 25, 2020. The
126 last version of the approved protocol, translated to English for publication purposes, is
127 available in S1 File. Ethical approval and informed consent form are in the S2 and S3
128 Files. A detailed description of procedures is available in the Manual of Procedures whose
129 last version is in the S4 File. This study followed the CONSORT recommendations for
130 reporting clinical trials (S5 File).

131

132 ***Study population***

133 This trial was conducted in the Emergency Service and the Transfusion Medicine Service
134 of the Edgardo Rebagliati Martins National Hospital (HNERM), a tertiary care hospital
135 located in Lima, the capital of Peru. Between September 2020 and April 2021, patients
136 who met the following inclusion criteria were enrolled:

137 1. Adult male or female patient ≥ 18 years of age requiring hospitalization or
138 hospitalized for COVID-19 without the need for mechanical ventilation (invasive
139 or non-invasive) at the time of enrollment.

140 2. Written informed consent before performing study procedures.

141 3. Laboratory-confirmed diagnosis of SARS-CoV-2 infection by RT-PCR in
142 nasopharyngeal or oropharyngeal swabs.

143 4. Patients at risk of progression of COVID-19 defined as the presence of two or
144 more of the following laboratory values:

145 a. Ferritin > 500 ng/mL

146 b. D-dimer > 1 mg/L

- 147 c. C-reactive protein > 15 mg/L
- 148 d. Total lymphocytes <1000/mm³ or neutrophil/lymphocyte ratio >3.13
- 149 5. Or patients with a clinical manifestation of pulmonary compromise defined by
- 150 the presence of two or more of the following clinical parameters
- 151 a. Dyspnoea
- 152 b. Respiratory rate greater than or equal to 30 per minute
- 153 c. Oxygen saturation less than 93%
- 154 d. PaO₂/FiO₂ less than 300 and pulmonary infiltrate greater than 50% in
- 155 the 24 to 48 hours after the initial evaluation

156 Likewise, patients who met any of the following criteria were excluded:

- 157 1. Transfusion of any blood product within 120 days before administration of
- 158 convalescent plasma.
- 159 2. Active pregnancy detected by a qualitative test that detects the hormone human
- 160 chorionic gonadotropin (hCG) in the urine.
- 161 3. Current participation in a randomized clinical trial or past involvement in a
- 162 clinical trial, and less than 30 days have passed since your last study visit.
- 163 4. Patient has life-threatening COVID-19 illness defined as one or more of the
- 164 following:
- 165 a. Respiratory failure, ventilatory type, defined as the need for invasive
- 166 mechanical ventilation (with endotracheal intubation) or ECMO
- 167 (extracorporeal oxygenation).
- 168 b. Septic shock, defined as having criteria for sepsis (an increase of two or
- 169 more points on the Sequential Organ Failure Assessment (SOFA) scale)
- 170 (17) and requiring vasopressors to maintain MAP \geq 65 mmHg after
- 171 adequate hydration.

172 c. Multiple organ dysfunction or failure, defined as the dysfunction of two
173 or more systems other than the respiratory system. System dysfunction will
174 be considered when a score of 2 or more is obtained on the SOFA scale in
175 the following systems: coagulation, liver, cardiovascular, central nervous
176 system, or kidney. The SOFA criteria used in this clinical trial are in the
177 S1 Table.

178 ***Study intervention***

179 All participants received SoC for COVID-19. In addition, the treatment arm received
180 ABO blood group system-compatible convalescent plasma from recovered COVID-19
181 patients (called donors) as an add-on therapy to the SoC. Other compatibilities, such as
182 the Rh factor, were unnecessary for the plasma transfusion since it is free of red blood
183 cells. Once a patient was assigned to the CP treatment arm, the CP bag was thawed, stored
184 at 2-6°C, and used within 24 hours. A complete unit of plasma was administered
185 intravenously as one dose, with a volume between 200-400 mL of convalescent plasma
186 contained in a transfusion bag, at a recommended flow rate of 150-200 mL/h or less
187 depending on patient tolerance. The plasma transfusion was in charge of one health
188 personnel from the Transfusion Medicine Service who fulfilled the role of transfuser and
189 was not part of the research team. The control arm received only SoC for COVID-19.

190 ***Outcomes***

191 The study's primary outcome was the cumulative incidence of mortality (all causes)
192 through day 28 after CP administration. Secondary outcomes were:

- 193 • Cumulative incidence of ICU admission at 14 and 28 days.
- 194 • Cumulative incidence of mechanical ventilation or extracorporeal oxygenation
195 (ECMO) on day 14 and day 28 after randomization.

196 • Cumulative incidence of mortality (all causes) on days 14 and 56 after CP
197 administration.

198 • Safety evaluations of CP + SoC compared to SoC alone up to day 28 considering
199 the cumulative incidence of serious adverse events (SAEs) and infusion-related
200 adverse reactions.

201 *Sample size*

202 For an open-label, parallel-group, standard-of-care, controlled, randomized (1:1 ratio)
203 superiority clinical trial and cumulative incidence of all-cause mortality at day 28 as the
204 primary outcome, a sample size of 190 patients (95 per arm) assuming 21% mortality in
205 the SoC arm (18) and an absolute difference of ~14% (relative risk of 0.33 or ~7%
206 mortality in the CP arm), with a power statistic of 80% and a two-sided alpha level of 5%
207 for a chi-square test of homogeneity without continuity correction. In addition, he
208 estimated that approximately 63 PC donors would be needed.

209 *Procedures*

210 The patients with COVID-19 were recruited at the HNERM Emergency Department
211 through daily screening of medical records or on-site identification of the patients. Donors
212 were invited through local print and audiovisual media advertising, which the Ethics
213 Committee previously approved. Potentially eligible candidates were invited for a
214 complete evaluation at the Blood Bank of the HNERM Transfusion Medicine Service.

215

216 The investigators of this study, certified and trained in Good Clinical Practices and Ethics
217 in Research in Humans, conducted the process of obtaining the subject's informed consent
218 in accordance with Peruvian regulations and internationally accepted standards.

219 The patients received a presentation with key aspects of the clinical trial, they read the
220 written informed consent document together with the investigator and their doubts were

221 answered by him. In the end, the researcher confirmed that the information provided in
222 the consent has been understood. When there were no more questions and the patient
223 expressed understanding of the informed consent document, they were asked if she wishes
224 to participate in the study. If accepted, the informed consent form was signed in duplicate
225 by the patient or her legal representative, in case the patient is incapacitated, and by one
226 of the researchers. In case she did not want to sign but did consent, her fingerprint was
227 placed. Finally, one original informed consent form was delivered to the patient, and the
228 other original was filed in a safe place. When the condition and severity of the patients
229 who cannot consent did not allow the taking of informed consent in writing, consent was
230 taken orally, recording the process in audiovisual media or digital images; and then, when
231 feasible, obtaining the signature of the research subject in the written informed consent
232 format. Due to the impediment to receiving medical visits that the COVID-19 services
233 have imposed on the relatives of hospitalized patients, it was possible to contact legal
234 representatives or relatives by phone or instant messaging to request their support or
235 consent if the participant is prevented from doing so. Donors also received information
236 about the clinical trial and gave their written informed consent before donating
237 convalescent plasma. Patients and donors were informed about the possibility of
238 collecting and storing an additional serum and plasma sample for up to one year for future
239 use in research related to SARS-CoV-2. If they accepted, the participant or her legal
240 representative signed written informed consent for future use of the biological sample.

241

242 Participants were randomly assigned to SoC alone (control arm) or treatment group (CP
243 + SoC) with a 1:1 allocation according to a computer random number generator program
244 that used permuted blocks of random size to ensure the balance of arms and the
245 unpredictability of treatment assignments at any time during the trial. The random

246 sequence was generated using the ado ralloc package (19) in Stata/SE version 16.1 for
247 Microsoft Windows Pro 10 (StataCorp. 2019. College Station, TX: StataCorp LLC.).
248 To ensure concealment, block sizes were not disclosed until endpoint analysis and a
249 central randomization scheme were implemented. The random assignment list was
250 generated by a randomization officer and was kept hidden without sharing with any
251 research team member until the clinical trial was completed. The randomization officer
252 was a member of the team who was not part of the staff of evaluators or therapists, so
253 integrity was guaranteed during the randomization process. A detailed timeline is
254 provided in S1 Fig.

255

256 *Statistical analysis*

257 The primary outcome was the cumulative incidence of death at 28 days after
258 randomization. This analysis was by intention to treat. The effect of CP + SoC versus
259 SoC alone on the cumulative incidence of mortality at 28 days was estimated using an
260 adjusted relative risk (aRR) obtained from a log-binomial regression model that included
261 the treatment variable and the block variable. Estimating the effect on mortality at 14 days
262 followed the same approach described. However, the effect on 56-day mortality was
263 assessed using a Cox regression that included treatment and block factor as covariates.
264 The effect of CP + SoC versus SoC alone on these outcomes was estimated using adjusted
265 hazard rate (HR) ratios. Survival curves were calculated using the Kaplan-Meier method
266 and compared using the log-rank test. The effect of CP + SoC on admission to the ICU
267 (at 14 and 28 days) and admission to mechanical ventilation (at 14 and 28 days),
268 compared to SoC alone, was estimated using the sub-hazard ratio (subHR) considering
269 death as a competitive event and obtained from a Fine and Gray model. Cumulative
270 incidence functions were estimated and compared using Gray test. All analyzes were

271 estimated with a 95% confidence interval and a significance level of 5%. Statistical
272 analyzes were performed with R version 4.1.3 software.

273

274 **Results**

275 *Patients*

276 Between September 2020 and April 2021, 64 research subjects who met the selection
277 criteria were enrolled, randomly assigning 32 to each study arm; One participant
278 randomized to the intervention arm withdrew from the study before the application of PC,
279 so 31 patients were assigned to convalescent plasma plus standard treatment and 32 to
280 standard treatment alone (Fig 1).

281

282 **Fig 1.** Enrollment and random assignment

283

284 The mean age of the patient population was 59.5 years (IQR: 46 to 72); 20.0% were
285 women, and 20% had at least one comorbidity at study entry. The median time from onset
286 of COVID-19 symptoms to enrollment was 13 days. The distribution of
287 sociodemographic and clinical characteristics is shown in Table 1.

288

289 **Table 1.** Characteristics of the participants at enrollment

Characteristics	CP + SoC (n = 32)	Only SoC (n = 32)
Sex		
Male	23 (71.9%)	28 (87.5%)
Female	9 (28.1%)	4 (12.5%)
Age, years	62.5 (51.8, 72.0)	56.5 (46.0, 69.0)
Arterial hypertension	6 (18.8%)	6 (18.8%)
Mellitus diabetes	4 (12.5%)	6 (18.8%)
Pulmonary fibrosis	0 (0.0%)	1 (3.1%)
Asthma	0 (0.0%)	1 (3.1%)
Heart disease	1 (3.1%)	1 (3.1%)
Cerebrovascular disease	0 (0.0%)	1 (3.1%)

Obesity	9 (28.1%)	7 (21.9%)
Cancer	1 (3.1%)	1 (3.1%)
Hypothyroidism	0 (0.0%)	2 (6.2%)
Hemoglobin, g/dL	14.0 (13.2, 15.3)	14.4 (13.2, 15.3)
Hemoglobin categories		
<14 g/dL	14 (45.2%)	14 (43.8%)
14-18 g/dL	17 (54.8%)	17 (53.1%)
>=18 g/dL	0 (0.0%)	1 (3.1%)
Lymphocyte count, 1/uL	760.0 (625.0, 1,060.0)	890.0 (737.5, 1,542.5)
Hemoglobin categories		
<900/uL	19 (61.3%)	16 (50.0%)
900-5200/uL	12 (38.7%)	16 (50.0%)
Neutrophil count, 1/uL	9,360.0 (6,670.0, 12,845.0)	7,520.0 (4,495.0, 9,385.0)
Neutrophil Count Categories		
1800-8000/uL	12 (38.7%)	17 (53.1%)
>8000/uL	19 (61.3%)	15 (46.9%)
Platelet count, 1000/uL	318.0 (214.0, 420.5)	262.5 (179.5, 380.0)
Platelet Count Categories		
<130 x 1000/uL	2 (6.5%)	2 (6.2%)
130-400 x 1000/uL	19 (61.3%)	23 (71.9%)
>400 x 1000/uL	10 (32.3%)	7 (21.9%)
Prothrombin time, sec	11.1 (10.6, 11.9)	11.0 (10.6, 11.9)
PT Categories		
<10.5 seg	6 (20.0%)	5 (15.6%)
10.5-13.0 seg	22 (73.3%)	25 (78.1%)
>13.0 seg	2 (6.7%)	2 (6.2%)
Partial thromboplastin time, sec	36.1 (32.2, 39.6)	34.0 (31.7, 36.4)
TPT Categories		
24.0-37.0 seg	0 (0.0%)	0 (0.0%)
>37.0 seg	12 (100.0%)	7 (100.0%)
Serum glucose, mg/dL	136.0 (118.0, 183.0)	137.0 (99.8, 185.5)
Serum glucose categories		
74-106 mg/dL	3 (9.7%)	10 (31.2%)
>106 mg/dL	28 (90.3%)	22 (68.8%)
Serum creatinine, mg/dL	0.7 (0.6, 0.8)	0.8 (0.7, 0.9)
Glutamic-oxalacetic transaminase, U/L	50.0 (39.0, 82.5)	58.5 (41.0, 67.5)
TGO Categories		
0.0-34.9 U/L	0 (0.0%)	0 (0.0%)
>34.9 U/L	25 (100.0%)	25 (100.0%)
Glutamic-pyruvic transaminase, U/L	75.0 (48.0, 119.5)	69.5 (51.2, 116.5)
TGP Categories		
0.0-49.0 U/L	8 (25.8%)	8 (25.0%)
>49.0 U/L	23 (74.2%)	24 (75.0%)
Serum sodium, mmol/L	139.2 (136.8, 142.1)	139.2 (136.8, 140.8)
Serum sodium categories		

<132.0 mmol/L	1 (3.2%)	0 (0.0%)
132.0-146.0 mmol/L	30 (96.8%)	32 (100.0%)
Serum potassium, mmol/L	4.1 (3.9, 4.4)	4.2 (4.0, 4.4)
Serum potassium categories		
<3.5 mmol/L	1 (3.3%)	1 (3.1%)
3.5-5.5 mmol/L	29 (96.7%)	31 (96.9%)
C-Reactive Protein, mg/dL	9.2 (5.1, 15.4)	6.1 (3.2, 11.2)
PCR Categories		
0.0-100.0 mg/dL	31 (100.0%)	31 (100.0%)
Ferritin, ng/mL	822.0 (666.9, 1,446.0)	869.9 (575.6, 1,362.5)
Ferritin Categories		
28.0-365.0 ng/dL	3 (9.7%)	4 (12.5%)
>365.0 ng/dL	28 (90.3%)	28 (87.5%)
D-dimer, mg/mL	0.7 (0.4, 1.1)	0.6 (0.5, 0.9)
D-Dimer Category		
0.00-0.54 ug/mL	11 (39.3%)	12 (40.0%)
>0.54 ug/mL	17 (60.7%)	18 (60.0%)
Lactic dehydrogenase, U/L	390.0 (289.5, 479.0)	347.5 (245.0, 403.8)
DHL Categories		
120.0-246.0 U/L	5 (16.1%)	9 (28.1%)
>246.0 U/L	26 (83.9%)	23 (71.9%)
Quantification of anti-SARS-CoV-2 antibodies - IgG, AU/mL	39.5 (15.9, 69.1)	37.8 (16.7, 67.5)
Categories of Ab anti-SARS-CoV-2 IgG		
Non-reactive	4 (12.9%)	7 (21.9%)
Reactive	27 (87.1%)	25 (78.1%)
Quantification of anti-SARS-CoV-2 antibodies - IgM, AU/mL	10.7 (2.3, 59.7)	5.4 (2.0, 23.8)
Categories of Ab anti-SARS-CoV-2 IgM		
Non-reactive	15 (48.4%)	20 (62.5%)
Reactive	16 (51.6%)	12 (37.5%)
Pulmonary compromise by tomography	50.0 (40.0, 63.0)	50.0 (42.0, 55.0)

CP + SoC: Convalescent plasma plus standard of care; SoC: Standard of care alone.

290

291 ***Primary outcome and secondary mortality outcomes***

292 The 28-day mortality was 25.8% (8 of 26 patients) in the convalescent plasma plus
293 standard therapy group and 12.5% (4 of 12 patients) in the standard therapy alone group.

294 At day 28, although mortality in the CP + SoC group was twice that of SoC, these
295 differences were not statistically significant (RR = 2.06; 95% CI 0.73 to 7.11; p = 0.190).

296

297 **Table 2.** Clinical Results in patients who received CP + SoC compared with SoC only.

Outcomes	Only SoC (n = 32)	CP + SoC (n = 31)	Risk Ratio or Hazard Ratio (95% CI); valor p
Primary outcome, death at 28 days; No. events (%)	4 (12)	8 (26)	Risk ratio; 2.06 (0.73 a 7.11); 0.190
Secondary outcomes			
Death at 14 days; No. events (%)	4 (12)	7 (23)	Risk ratio; 2.06 (0.73 a 7.11); 0.190
Time to ICU admission in 14 days; n events/person-time	3 (384)	6 (311)	Subhazard ratio; 2.21 (0.57 a 8.55); 0.250
Time to ICU admission in 28 days; n events/person-time	3 (720)	6 (577)	Subhazard ratio; 2.21 (0.57 a 8.55); 0.250
Time to invasive mechanical ventilation in 14 days; n events/person-time	3 (382)	6 (311)	Subhazard ratio; 2.30 (0.60 a 8.84); 0.230
Time to invasive mechanical ventilation in 28 days; n events/person-time	3 (718)	6 (577)	Subhazard ratio; 2.19 (0.57 a 8.51); 0.260
Time to death in 56 days; n events / person days	4 (1473)	8 (1339)	Hazard ratio; 2.56 (0.72 a 9.08); 0.147
Adverse events; No. events (%)			
Any event	6 (19)	12 (39)	Odds ratio; 2.74 (0.90 a 9.10); 0.085
Serious event	2 (6.2)	6 (19)	Odds ratio; 3.60 (0.75 a 26.1); 0.14
Infusion related event	0	0	NA

298 NA: Not apply

299

300 In the 56 days after enrollment, no statistically significant differences were found in the
301 cumulative incidence curves of both groups ($p = 0.196$) (Fig 2). Similarly, there were no
302 significant differences in the incidences of mortality (HR 2.21, 95% CI 0.66 to 7.33; p
303 value = 0.182) (Table 2). The proportionality assumption of the Cox regression hazards
304 was supported by the Grambsch and Therneau test ($p = 0.450$) and the Schoenfeld residual
305 inspection.

306

307 **Fig 2.** Inverse Kaplan-Meier curves for cumulative incidence of death after treatment with
308 CP + SoC versus SoC alone

309

310 *Secondary efficacy outcomes*

311 No statistically significant differences were found in the cumulative incidence curves for
312 admission to the ICU within 28 days ($p = 0.251$) (Fig 3A). The incidence rate of admission
313 to the ICU within 28 days was 10.4 per 1000 patient days in the CP + SoC group and 4.17
314 per 1000 patient days in the group that received only SoC. Considering death as a
315 competitive event, the Fine and Gray model revealed no statistically significant
316 differences in the incidence of ICU admission between both groups (subHR 2.06; 95%
317 CI 0.57 to 8.55; $p = 0.250$). Compared to standard treatment alone, the estimated effect
318 of convalescent plasma + standard treatment was the same for ICU admission at 14 days
319 (subHR 2.21; 95% CI 0.57 to 8.55; $p = 0.250$).

320

321 No statistically significant differences were found in the cumulative incidence curves for
322 admission to mechanical ventilation at 28 days ($p = 0.256$) (Fig 3B). The 28-day incidence
323 rate of invasive mechanical ventilation was 10.4 per 1,000 patient days in the
324 convalescent plasma plus standard therapy group and 4.18 per 1,000 patient days in the
325 standard therapy only group. Compared to standard treatment alone, the estimated effect
326 of convalescent plasma + standard treatment was the same for admission to mechanical
327 ventilation at 28 days (subHR 2.19; 95% CI 0.57 to 8.51; $p = 0.260$).

328

329 **Fig 3.** Cumulative incidence function curves for death (competing event) and (A) ICU
330 admission or (B) mechanical ventilator admission after treatment with CP + SoC versus
331 SoC alone

332

333 *Safety results*

334 No infusion-related adverse events were reported in study participants. Adverse events

335 were more common in the CP + SoC group (39%; 12 of 31 patients) than in the SoC
336 group (19%; 6 of 32 patients). Similarly, serious adverse events were slightly more
337 common in the CP + SoC group (19%; 6 of 31 patients) than in the SoC group (6.2%; 2
338 of 32 patients). However, there is high uncertainty regards the differences in the incidence
339 of adverse events (OR 2.74; 95% CI, 0.90 to 9.10; $p = 0.085$) or serious adverse events
340 (OR 3.60; 95% CI 0.75 to 26.1; $p = 0.75$) (Table 2 and S1 Table) if we consider the
341 precision of these estimates and statistical significance.

342

343 **Discussion**

344 This study aimed to assess the efficacy and safety of convalescent plasma (CP) plus
345 standard of care (SoC) versus SoC alone in adult patients hospitalized with COVID-19
346 but not yet requiring mechanical ventilation. Our results found no evidence that PC had
347 an effect in reducing mortality at 28 days. We also found no evidence that the frequency
348 of adverse events was higher in those who received PC than those who received SoC.

349

350 Our results agree with those widely reported in the literature. Although initially,
351 systematic reviews with meta-analyses (24-26) found evidence of benefit in favor of PC
352 to reduce mortality, these included observational studies (27–30) and clinical trials with
353 significant limitations (18,31). More recent clinical trials reported no evidence of the
354 benefit of PC in reducing mortality, admission to the ICU, or mechanical ventilation
355 (17,32-45). Later meta-analyses also concluded no evidence of PC efficacy in reducing
356 the incidence of these outcomes (8,24,25,38,46–52). Clinical practice guidelines
357 recommend against using PC in hospitalized patients with COVID-19 with a strong level
358 of recommendation and a high certainty of evidence (14,15,53).

359

360 The RECOVERY (34), CONCOR-1 (44), and REMAP-CAP (45) studies were the three
361 largest clinical trials conducted to assess the efficacy and safety of convalescent plasma,
362 and none found evidence of a benefit of high-dose CP in reducing mortality, ICU
363 admission or mechanical ventilation in patients with COVID-19. Like our study, all of
364 them were open-label and were stopped early. The RECOVERY trial (34) enrolled 11,558
365 patients (5,795 received CP + SoC and 5,763 received SoC). The study found evidence
366 in favor of no significant differences (RR = 1.00; 95% CI 0.93-1.07) in 28-day mortality
367 and other hospital outcomes such as mechanical ventilation. The CONCOR-1 trial (44),
368 which enrolled 614 patients in the CP group and 307 in the SoC group, found no
369 significant difference in its primary outcome of intubation or death at day 30 (RR = 1.16;
370 95%CI 0.94-1.43) nor in its secondary outcomes such as mortality, admission to intensive
371 care and hospital stay. The REMAP-CAP trial (45), which enrolled 1084 critically ill
372 patients in the PC group, and 916 in the control group, found no significant differences
373 in in-hospital mortality outcomes. However, it did report potential for harm in patients
374 who received convalescent plasma after the seven days of hospitalization.

375

376 Regarding the safety of PC, to date, 51 clinical trials have been published that evaluated
377 the use of PC, concluding, through a meta-analysis, that with a low degree of certainty,
378 PC does not increase the occurrence of adverse events (15). Consistent with existing
379 evidence, our study did not find any transfusion-related SAEs and, although there was a
380 higher frequency of adverse events of any kind in the group treated with PC + SoC
381 compared to the SoC group, these differences were not statistically significant.

382

383 Observational surveillance studies suggest that adverse reactions are infrequent and
384 related to conventional risks of plasma infusion for other indications. For example, a study

385 evaluating safety using records from 5,000 clinicians of hospitalized adult patients with
386 severe COVID-19 found a low mortality rate of 0.3%. Likewise, the incidence of all
387 serious adverse events (SAEs) in the first four hours after the transfusion was less than
388 1% (54). In addition to death (4 cases of 25 related SAEs), the main SAEs were
389 transfusion-related circulatory overload (7 of 25 related SAEs), transfusion-related acute
390 lung injury (11 of 25 SAEs), and severe transfusion-related allergic reactions (3 of 25
391 EAS). Months later, the update of this study extended the analysis to 20,000 patients,
392 confirming the low frequency of adverse events: <1% for thrombotic and
393 thromboembolic events and ~3% for cardiac events (55).

394

395 This study has limitations to be considered. All patients had moderate to severe COVID-
396 19, so our conclusions cannot be extrapolated to other groups of patients with different
397 degrees of severity, especially patients with mild COVID-19. Another limitation is that
398 the trial was open label, which could have influenced more subjective outcomes such as
399 the recognition and/or reporting of some adverse events. However, these results are
400 unlikely to have influenced hard outcomes such as mortality, ICU admission, or
401 admission to mechanical ventilation.

402

403 In conclusion, in our study, using CP + SoC in patients with moderate COVID-19 did
404 not reduce mortality or improve other clinical outcomes at day 28 compared to SoC
405 alone. Our results are consistent with the literature on the lack of benefit of CP and
406 reinforce the evidence in favor of discouraging CP use in hospitalized patients with
407 moderate to severe COVID-19.

408

409 **References**

- 410 1. Ciotti M, Angeletti S, Minieri M, Giovannetti M, Benvenuto D, Pascarella S, et al.
411 COVID-19 Outbreak: An Overview. *Chemotherapy*. 2019;64(5–6):215–23.
- 412 2. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus from
413 Patients with Pneumonia in China, 2019. *N Engl J Med*. 2020 Feb 20;382(8):727–
414 33.
- 415 3. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and
416 epidemiology of 2019 novel coronavirus: implications for virus origins and
417 receptor binding. *The Lancet*. 2020 Feb 22;395(10224):565–74.
- 418 4. Asili P, Mirahmad M, Tabatabaei-Malazy O, Manayi A, Haghghat E, Mahdavi M,
419 et al. Characteristics of published/registered clinical trials on COVID-19 treatment:
420 A systematic review. *Daru J Fac Pharm Tehran Univ Med Sci*. 2021
421 Dec;29(2):449–67.
- 422 5. Marson P, Cozza A, De Silvestro G. The true historical origin of convalescent
423 plasma therapy. *Transfus Apher Sci*. 2020 Oct;59(5):102847.
- 424 6. Marano G, Vaglio S, Pupella S, Facco G, Catalano L, Liumbruno GM, et al.
425 Convalescent plasma: new evidence for an old therapeutic tool? *Blood Transfus*.
426 2016 Mar;14(2):152–7.
- 427 7. Rojas M, Rodríguez Y, Monsalve DM, Acosta-Ampudia Y, Camacho B, Gallo JE,
428 et al. Convalescent plasma in Covid-19: Possible mechanisms of action.
429 *Autoimmun Rev*. 2020 Jul;19(7):102554.
- 430 8. Vegivinti CTR, Pederson JM, Saravu K, Gupta N, Evanson KW, Kamrowski S, et
431 al. Efficacy of convalescent plasma therapy for COVID-19: A systematic review
432 and meta-analysis. *J Clin Apheresis* [Internet]. [cited 2021 May 14];n/a(n/a).
433 Available from: <https://onlinelibrary.wiley.com/doi/abs/10.1002/jca.21881>
- 434 9. Piechotta V, Chai KL, Valk SJ, Doree C, Monsef I, Wood EM, et al. Convalescent
435 plasma or hyperimmune immunoglobulin for people with COVID-19: a living
436 systematic review. *Cochrane Database Syst Rev* [Internet]. 2020 Jul 10 [cited 2021
437 Feb 8];(7). Available from:
438 <https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013600.pub2/full>
- 439 10. Wang Y, Huo P, Dai R, Lv X, Yuan S, Zhang Y, et al. Convalescent plasma may
440 be a possible treatment for COVID-19: A systematic review. *Int*
441 *Immunopharmacol*. 2021 Feb;91:107262.
- 442 11. Janiaud P, Axfors C, Schmitt AM, Gloy V, Ebrahimi F, Hepprich M, et al.
443 Association of Convalescent Plasma Treatment With Clinical Outcomes in
444 Patients With COVID-19: A Systematic Review and Meta-analysis. *JAMA*. 2021
445 Mar 23;325(12):1185–95.
- 446 12. Piscocoya A, Ng-Sueng LF, Riego AP del, Cerna-Viacava R, Pasupuleti V, Thota P,
447 et al. Efficacy and harms of convalescent plasma for treatment of hospitalized
448 COVID-19 patients: a systematic review and meta-analysis. *Arch Med Sci*
449 [Internet]. 2021 Feb 18 [cited 2021 May 14]; Available from:

- 450 [https://www.archivesofmedicalscience.com/Efficacy-and-harms-of-convalescent-](https://www.archivesofmedicalscience.com/Efficacy-and-harms-of-convalescent-plasma-for-treatment-of-hospitalized-COVID-19,132492,0,2.html)
451 [plasma-for-treatment-of-hospitalized-COVID-19,132492,0,2.html](https://www.archivesofmedicalscience.com/Efficacy-and-harms-of-convalescent-plasma-for-treatment-of-hospitalized-COVID-19,132492,0,2.html)
- 452 13. Piechotta V, Iannizzi C, Chai KL, Valk SJ, Kimber C, Dorando E, et al.
453 Convalescent plasma or hyperimmune immunoglobulin for people with
454 COVID-19: a living systematic review. *Cochrane Database Syst Rev* [Internet].
455 2021 [cited 2022 Apr 19];(5). Available from:
456 <https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013600.pub4/ap>
457 [pendices](https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013600.pub4/ap)
- 458 14. Bartoletti M, Azap O, Barac A, Bussini L, Ergonul O, Krause R, et al. ESCMID
459 COVID-19 living guidelines: drug treatment and clinical management. *Clin*
460 *Microbiol Infect*. 2022 Feb;28(2):222–38.
- 461 15. Therapeutics and COVID-19: living guideline [Internet]. [cited 2022 Apr 19].
462 Available from: [https://www.who.int/publications-detail-redirect/WHO-2019-](https://www.who.int/publications-detail-redirect/WHO-2019-nCoV-therapeutics-2022.2)
463 [nCoV-therapeutics-2022.2](https://www.who.int/publications-detail-redirect/WHO-2019-nCoV-therapeutics-2022.2)
- 464 16. Bajpai M, Maheshwari A, Dogra V, Kumar S, Gupta E, Kale P, et al. Efficacy of
465 convalescent plasma therapy in the patient with COVID-19: a randomised control
466 trial (COPLA-II trial). *BMJ Open*. 2022 Apr 6;12(4):e055189.
- 467 17. Agarwal A, Mukherjee A, Kumar G, Chatterjee P, Bhatnagar T, Malhotra P.
468 Convalescent plasma in the management of moderate covid-19 in adults in India:
469 open label phase II multicentre randomised controlled trial (PLACID Trial). *BMJ*.
470 2020 Oct 22;371:m3939.
- 471 18. Libster R, Pérez Marc G, Wappner D, Coviello S, Bianchi A, Braem V, et al. Early
472 High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults. *N Engl J*
473 *Med*. 2021 Feb 18;384(7):610–8.
- 474 19. Hartmann J, Bloch EM, Burnouf T. Experience with COVID-19 convalescent
475 plasma provides vital guidance to future pandemics. *Transfusion (Paris)*.
476 2022;62(3):681–4.
- 477 20. Paneth N, Casadevall A, Pirofski L, Henderson JP, Grossman BJ, Shoham S,
478 et al. WHO covid-19 drugs guideline: reconsider using convalescent plasma. *BMJ*.
479 2022 Feb 8;376:o295.
- 480 21. Joyner MJ, Paneth NS, Senefeld JW, Fairweather D, Bruno KA, Wright RS, et al.
481 Concerns about estimating relative risk of death associated with convalescent
482 plasma for COVID-19. *Nat Med*. 2022 Jan;28(1):51–2.
- 483 22. Schulz KF, Altman DG, Moher D. CONSORT 2010 Statement: updated guidelines
484 for reporting parallel group randomised trials. *BMJ*. 2010 Mar 24;340:c332.
- 485 23. ENSAYOS CLINICOS - INSTITUTO NACIONAL DE SALUD [Internet]. [cited
486 2022 May 4]. Available from:
487 <https://www.ins.gob.pe/ensayosclinicos/rpec/recuperarECPBNuevoEN.asp?numec>
488 [=013-20](https://www.ins.gob.pe/ensayosclinicos/rpec/recuperarECPBNuevoEN.asp?numec)

- 489 24. Meher BR, Padhy BM, Das S, Mohanty RR, Agrawal K. Effectiveness of
490 Convalescent Plasma Therapy in the Treatment of Moderate to Severe COVID 19
491 Patients: A Systematic Review and Meta-Analysis. *J Assoc Physicians India*. 2020
492 Dec;68(12):35–43.
- 493 25. Kim MS, An MH, Kim WJ, Hwang TH. Comparative efficacy and safety of
494 pharmacological interventions for the treatment of COVID-19: A systematic
495 review and network meta-analysis. *PLOS Med*. 2020 Dec 30;17(12):e1003501.
- 496 26. Klassen SA, Senefeld JW, Johnson PW, Carter RE, Wiggins CC, Shoham S, et al.
497 The Effect of Convalescent Plasma Therapy on Mortality Among Patients With
498 COVID-19: Systematic Review and Meta-analysis. *Mayo Clin Proc*. 2021 May
499 1;96(5):1262–75.
- 500 27. Joyner MJ, Carter RE, Senefeld JW, Klassen SA, Mills JR, Johnson PW, et al.
501 Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19. *N*
502 *Engl J Med*. 2021 Mar 18;384(11):1015–27.
- 503 28. Liu STH, Lin HM, Baine I, Wajnberg A, Gumprecht JP, Rahman F, et al.
504 Convalescent plasma treatment of severe COVID-19: a propensity score-matched
505 control study. *Nat Med*. 2020 Nov;26(11):1708–13.
- 506 29. Salazar E, Christensen PA, Graviss EA, Nguyen DT, Castillo B, Chen J, et al.
507 Significantly Decreased Mortality in a Large Cohort of Coronavirus Disease 2019
508 (COVID-19) Patients Transfused Early with Convalescent Plasma Containing
509 High-Titer Anti–Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-
510 2) Spike Protein IgG. *Am J Pathol*. 2021 Jan;191(1):90–107.
- 511 30. Briggs N, Gormally MV, Li F, Browning SL, Treggiari MM, Morrison A, et al.
512 Early but not late convalescent plasma is associated with better survival in
513 moderate-to-severe COVID-19. *PloS One*. 2021;16(7):e0254453.
- 514 31. O’Donnell MR, Grinsztejn B, Cummings MJ, Justman JE, Lamb MR, Eckhardt
515 CM, et al. A randomized double-blind controlled trial of convalescent plasma in
516 adults with severe COVID-19. *J Clin Invest*. 2021 Jul 1;131(13):150646.
- 517 32. Li L, Zhang W, Hu Y, Tong X, Zheng S, Yang J, et al. Effect of Convalescent
518 Plasma Therapy on Time to Clinical Improvement in Patients With Severe and
519 Life-threatening COVID-19: A Randomized Clinical Trial. *JAMA*. 2020 Aug
520 4;324(5):460–70.
- 521 33. Simonovich VA, Burgos Pratz LD, Scibona P, Beruto MV, Vallone MG, Vázquez
522 C, et al. A Randomized Trial of Convalescent Plasma in Covid-19 Severe
523 Pneumonia. *N Engl J Med*. 2021 Feb 18;384(7):619–29.
- 524 34. RECOVERY Collaborative Group. Convalescent plasma in patients admitted to
525 hospital with COVID-19 (RECOVERY): a randomised controlled, open-label,
526 platform trial. *Lancet Lond Engl*. 2021 May 29;397(10289):2049–59.
- 527 35. Körper S, Weiss M, Zickler D, Wiesmann T, Zacharowski K, Corman VM, et al.
528 Results of the CAPSID randomized trial for high-dose convalescent plasma in
529 patients with severe COVID-19. *J Clin Invest*. 2021 Oct 15;131(20):e152264.

- 530 36. Avendaño-Solá C, Ramos-Martínez A, Muñoz-Rubio E, Ruiz-Antorán B, Malo de
531 Molina R, Torres F, et al. A multicenter randomized open-label clinical trial for
532 convalescent plasma in patients hospitalized with COVID-19 pneumonia. *J Clin*
533 *Invest*. 2021 Oct 15;131(20):e152740.
- 534 37. Baldeón ME, Maldonado A, Ochoa-Andrade M, Largo C, Pesantez M, Herdoiza
535 M, et al. Effect of convalescent plasma as complementary treatment in patients
536 with moderate COVID-19 infection. *Transfus Med Oxf Engl*. 2022
537 Apr;32(2):153–61.
- 538 38. Sekine L, Arns B, Fabro BR, Cipolatt MM, Machado RRG, Durigon EL, et al.
539 Convalescent plasma for COVID-19 in hospitalised patients: an open-label,
540 randomised clinical trial. *Eur Respir J*. 2022 Feb;59(2):2101471.
- 541 39. van den Berg K, Glatt TN, Vermeulen M, Little F, Swanevelder R, Barrett C, et al.
542 Convalescent plasma in the treatment of moderate to severe COVID-19
543 pneumonia: a randomized controlled trial (PROTECT-Patient Trial). *Sci Rep*.
544 2022 Feb 15;12(1):2552.
- 545 40. AlQahtani M, Abdulrahman A, Almadani A, Alali SY, Al Zamrooni AM, Hejab
546 AH, et al. Randomized controlled trial of convalescent plasma therapy against
547 standard therapy in patients with severe COVID-19 disease. *Sci Rep*. 2021 May
548 11;11:9927.
- 549 41. Rasheed AM, Fatak DF, Hashim HA, Maulood MF, Kabah KK, Almusawi YA, et
550 al. The therapeutic potential of convalescent plasma therapy on treating critically-
551 ill COVID-19 patients residing in respiratory care units in hospitals in Baghdad,
552 Iraq. *Infez Med*. 2020 Sep 1;28(3):357–66.
- 553 42. Ortigoza MB, Yoon H, Goldfeld KS, Troxel AB, Daily JP, Wu Y, et al. Efficacy
554 and Safety of COVID-19 Convalescent Plasma in Hospitalized Patients: A
555 Randomized Clinical Trial. *JAMA Intern Med*. 2022 Feb 1;182(2):115–26.
- 556 43. Holm K, Lundgren MN, Kjeldsen-Kragh J, Ljungquist O, Böttiger B, Wikén C, et
557 al. Convalescence plasma treatment of COVID-19: results from a prematurely
558 terminated randomized controlled open-label study in Southern Sweden. *BMC Res*
559 *Notes*. 2021 Dec 4;14(1):440.
- 560 44. Bégin P, Callum J, Jamula E, Cook R, Heddle NM, Tinmouth A, et al.
561 Convalescent plasma for hospitalized patients with COVID-19: an open-label,
562 randomized controlled trial. *Nat Med*. 2021 Nov;27(11):2012–24.
- 563 45. Writing Committee for the REMAP-CAP Investigators, Estcourt LJ, Turgeon AF,
564 McQuilten ZK, McVerry BJ, Al-Beidh F, et al. Effect of Convalescent Plasma on
565 Organ Support-Free Days in Critically Ill Patients With COVID-19: A
566 Randomized Clinical Trial. *JAMA*. 2021 Nov 2;326(17):1690–702.
- 567 46. Snow TAC, Saleem N, Ambler G, Nastouli E, McCoy LE, Singer M, et al.
568 Convalescent plasma for COVID-19: a meta-analysis, trial sequential analysis, and
569 meta-regression. *Br J Anaesth*. 2021 Dec;127(6):834–44.

- 570 47. Kloypan C, Saesong M, Sangsuemmoon J, Chantharit P, Mongkhon P.
571 CONVALESCENT plasma for COVID-19: A meta-analysis of clinical trials and
572 real-world evidence. *Eur J Clin Invest*. 2021 Nov;51(11):e13663.
- 573 48. Peng HT, Rhind SG, Beckett A. Convalescent Plasma for the Prevention and
574 Treatment of COVID-19: A Systematic Review and Quantitative Analysis. *JMIR*
575 *Public Health Surveill*. 2021 Apr 7;7(4):e25500.
- 576 49. Axfors C, Janiaud P, Schmitt AM, Van't Hooft J, Smith ER, Haber NA, et al.
577 Association between convalescent plasma treatment and mortality in COVID-19: a
578 collaborative systematic review and meta-analysis of randomized clinical trials.
579 *BMC Infect Dis*. 2021 Nov 20;21(1):1170.
- 580 50. Yang P, Wang J, Zheng R, Tan R, Li X, Liu X, et al. Convalescent plasma may not
581 be an effective treatment for severe and critically ill covid-19 patients: A
582 Systematic Review & Meta-Analysis of Randomized Controlled Trials. *Heart*
583 *Lung J Crit Care*. 2022 Jun;53:51–60.
- 584 51. Jorda A, Kussmann M, Kolenchery N, Siller-Matula JM, Zeitlinger M, Gilma B, et
585 al. Convalescent Plasma Treatment in Patients with Covid-19: A Systematic
586 Review and Meta-Analysis. *Front Immunol*. 2022;13:817829.
- 587 52. Troxel AB, Petkova E, Goldfeld K, Liu M, Tarpey T, Wu Y, et al. Association of
588 Convalescent Plasma Treatment With Clinical Status in Patients Hospitalized With
589 COVID-19: A Meta-analysis. *JAMA Netw Open*. 2022 Jan 4;5(1):e2147331.
- 590 53. Convalescent Plasma and Immune Globulins [Internet]. COVID-19 Treatment
591 Guidelines. [cited 2022 Apr 20]. Available from:
592 [https://www.covid19treatmentguidelines.nih.gov/therapies/anti-sars-cov-2-](https://www.covid19treatmentguidelines.nih.gov/therapies/anti-sars-cov-2-antibody-products/convalescent-plasma/)
593 [antibody-products/convalescent-plasma/](https://www.covid19treatmentguidelines.nih.gov/therapies/anti-sars-cov-2-antibody-products/convalescent-plasma/)
- 594 54. Joyner MJ, Wright RS, Fairweather D, Senefeld JW, Bruno KA, Klassen SA, et al.
595 Early safety indicators of COVID-19 convalescent plasma in 5000 patients. *J Clin*
596 *Invest*. 2020 Sep 1;130(9):4791–7.
- 597 55. Joyner MJ, Bruno KA, Klassen SA, Kunze KL, Johnson PW, Lesser ER, et al.
598 Safety Update. *Mayo Clin Proc*. 2020 Sep;95(9):1888–97.

medRxiv preprint doi: <https://doi.org/10.1101/2022.09.21.22280195>; this version posted September 23, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY 4.0 International license](https://creativecommons.org/licenses/by/4.0/).




Figure1





Figure2

A



B




Figure3